WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation

NYSE:WST • US9553061055

Current stock price

251.85 USD
+4.83 (+1.96%)
Last:

This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. WST Profitability Analysis

1.1 Basic Checks

  • In the past year WST was profitable.
  • WST had a positive operating cash flow in the past year.
  • Each year in the past 5 years WST has been profitable.
  • WST had a positive operating cash flow in each of the past 5 years.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 11.56%, WST belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
  • WST's Return On Equity of 15.54% is amongst the best of the industry. WST outperforms 89.29% of its industry peers.
  • WST has a better Return On Invested Capital (14.09%) than 92.86% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for WST is above the industry average of 12.34%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 14.09%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • With an excellent Profit Margin value of 16.06%, WST belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
  • WST's Profit Margin has been stable in the last couple of years.
  • Looking at the Operating Margin, with a value of 20.53%, WST belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
  • In the last couple of years the Operating Margin of WST has remained more or less at the same level.
  • With a Gross Margin value of 35.91%, WST is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of WST has remained more or less at the same level.
Industry RankSector Rank
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

8

2. WST Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so WST is still creating some value.
  • WST has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for WST has been reduced compared to 5 years ago.
  • The debt/assets ratio for WST has been reduced compared to a year ago.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 12.78 indicates that WST is not in any danger for bankruptcy at the moment.
  • WST has a better Altman-Z score (12.78) than 98.21% of its industry peers.
  • The Debt to FCF ratio of WST is 0.44, which is an excellent value as it means it would take WST, only 0.44 years of fcf income to pay off all of its debts.
  • WST has a Debt to FCF ratio of 0.44. This is amongst the best in the industry. WST outperforms 92.86% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that WST is not too dependend on debt financing.
  • The Debt to Equity ratio of WST (0.06) is better than 66.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Altman-Z 12.78
ROIC/WACC1.3
WACC10.83%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that WST has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.02, WST perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
  • WST has a Quick Ratio of 2.34. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.34, WST is in line with its industry, outperforming 55.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

4

3. WST Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 8.00% over the past year.
  • WST shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.94% yearly.
  • Looking at the last year, WST shows a small growth in Revenue. The Revenue has grown by 6.25% in the last year.
  • Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.50% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.60% on average over the next years.
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue Next Year6.04%
Revenue Next 2Y6.1%
Revenue Next 3Y6.43%
Revenue Next 5Y5.6%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

3

4. WST Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 34.55, which means the current valuation is very expensive for WST.
  • WST's Price/Earnings ratio is a bit cheaper when compared to the industry. WST is cheaper than 64.29% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.61. WST is valued slightly more expensive when compared to this.
  • Based on the Price/Forward Earnings ratio of 31.08, the valuation of WST can be described as expensive.
  • Based on the Price/Forward Earnings ratio, WST is valued a bit cheaper than the industry average as 62.50% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 22.79. WST is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 34.55
Fwd PE 31.08
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • WST's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. WST is cheaper than 67.86% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, WST is valued a bit cheaper than the industry average as 64.29% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 38.71
EV/EBITDA 21.46
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of WST may justify a higher PE ratio.
PEG (NY)3.1
PEG (5Y)3.86
EPS Next 2Y11.07%
EPS Next 3Y11.63%

6

5. WST Dividend Analysis

5.1 Amount

  • WST has a yearly dividend return of 0.32%, which is pretty low.
  • WST's Dividend Yield is rather good when compared to the industry average which is at 0.12. WST pays more dividend than 82.14% of the companies in the same industry.
  • With a Dividend Yield of 0.32, WST pays less dividend than the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has paid a dividend for at least 10 years, which is a reliable track record.
  • WST has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)5.48%
Div Incr Years32
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 12.40% of the earnings are spent on dividend by WST. This is a low number and sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12.4%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

WST Fundamentals: All Metrics, Ratios and Statistics

WEST PHARMACEUTICAL SERVICES

NYSE:WST (3/26/2026, 2:42:05 PM)

251.85

+4.83 (+1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-22
Inst Owners97.62%
Inst Owner Change-2.08%
Ins Owners0.33%
Ins Owner Change0.38%
Market Cap18.15B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target328.99 (30.63%)
Short Float %3.32%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years32
Div Non Decr Years34
Ex-Date04-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)-6.91%
PT rev (3m)-5.85%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)1.86%
EPS NY rev (1m)3.22%
EPS NY rev (3m)3.47%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE 34.55
Fwd PE 31.08
P/S 5.91
P/FCF 38.71
P/OCF 24.05
P/B 5.72
P/tB 5.94
EV/EBITDA 21.46
EPS(TTM)7.29
EY2.89%
EPS(NY)8.1
Fwd EY3.22%
FCF(TTM)6.51
FCFY2.58%
OCF(TTM)10.47
OCFY4.16%
SpS42.65
BVpS44.06
TBVpS42.43
PEG (NY)3.1
PEG (5Y)3.86
Graham Number85.01
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.45%
ROIC 14.09%
ROICexc 18.03%
ROICexgc 18.82%
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2103.33
Cash Conversion 94.07%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 12.78
F-Score7
WACC10.83%
ROIC/WACC1.3
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.04%
Revenue Next 2Y6.1%
Revenue Next 3Y6.43%
Revenue Next 5Y5.6%
EBIT growth 1Y7.88%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.23%
EBIT Next 3Y19.91%
EBIT Next 5Y13.54%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST Fundamental Analysis FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.


Can you provide the financial health for WST stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?

The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.4%.